Watch IRD. Know when insiders buy.
One email the day a filing lands. Free.
IRD
Opus Genetics, Inc.
4.34
−0.33 −7.07%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · insiders 44, shorts 41
Insiders, 90 days
−$127K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $361.1MP/E —DIV YIELD —FCF YIELD —REV TTM $9.9M −36.1%NET INCOME −$107.6MNET CASH $53.5M52W 1.33 – 5.75SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $755K | −73.8% | — | −$16.5M | −$8.1M | — | -0.14 | −$11.9M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $2.2M | −50.6% | — | −$14.4M | −$65.5M | — | -0.75 | −$12.7M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $3.9M | −10.2% | — | −$11.5M | −$16.5M | — | -0.21 | −$9.8M | — | — | Mar 12 |
| Q3 2025 · Sep 30 | $3.1M | −20.4% | — | −$8.3M | −$17.5M | — | -0.25 | −$6.2M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $2.9M | +159.2% | — | −$8.9M | −$7.4M | — | -0.12 | −$10.3M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $4.4M | +155.4% | — | −$9.9M | −$8.2M | — | -0.24 | −$9M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $4.3M | +154.4% | — | −$38M | −$35.1M | — | -1.27 | −$7.4M | — | — | Mar 12 |
| Q3 2024 · Sep 30 | $3.9M | −67.6% | — | −$8M | −$7.5M | −235.3% | -0.29 | −$5.1M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | $1.1M | — | — | −$8.3M | −$7.8M | — | -0.30 | −$7.3M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | $1.7M | — | — | −$7.7M | −$7.1M | — | -0.29 | −$5.7M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | $1.7M | — | — | −$5.4M | −$4.8M | — | -0.21 | $4.5M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | $11.9M | — | — | $6.4M | $5.6M | — | 0.25 | −$3M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $14.2M | — | −$38.6M | −$49.6M | -349.3% | -0.80 | −$35.3M | — | — | — | — |
| FY2024 · to Dec 31 | $11M | — | −$62.1M | −$57.5M | -523.4% | -2.15 | −$25.6M | — | — | — | — |
| FY2023 · to Dec 31 | $19M | — | −$10.6M | −$10M | -52.4% | -0.46 | −$1.1M | — | — | — | — |
| FY2022 · to Dec 31 | $39.9M | — | $18.2M | $17.9M | 44.9% | 0.87 | $14.3M | — | — | — | — |
| FY2021 · to Dec 31 | $589K | — | −$22.7M | −$56.7M | -9625.3% | -3.82 | −$19.4M | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | −$20M | −$24.6M | — | -5.28 | −$6.8M | $0 | −$6.8M | — | — |
Every number comes from Opus Genetics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.